ZOLMITRIPTAN BRAIN TARGETING VIA INTRANASAL ROUTE USING SOLID LIPID NANOPARTICLES FOR MIGRAINE THERAPY: FORMULATION, CHARACTERIZATION, IN-VITRO AND IN-VIVO ASSESSMENT

  • DALIA A. ELATY MOSTAFA Lecturer of Pharmaceutics, Faculty of Pharmacy, Pharmaceutics Department, October University for Modern Sciences and Arts (MSA) University
  • MAHA K. A. KHALIFA Lecturer of Pharmaceutics, Faculty of Pharmacy, Girls Branch, Al-Azhar University, Cairo, Egypt
  • SAMEH S. GAD Lecturer of Pharmacology and Toxicology, Faculty of Pharmacy, Pharmacology and Toxicology Department, October University for Modern Sciences and Arts (MSA) University

Abstract

Objective: Zolmitriptan, a class of antidepressant drugs with poor bioavailability due to its first-pass metabolism. The aim of this study was to improve systemic bioavailability and explore the brain targeting impact of nasal Zolmitriptan (Zol) solid lipid nanoparticles (SLNs) gel for migraine treatment. 


Methods: Stearic acid and cholesterol used as solid lipid and lecithin as a surfactant, emulsion solvent evaporation technique was used to produce Zolmitriptan SLNs. (Zol) SLNs were characterized for particle size, percent entrapment efficiency and in vitro drug release. Formula S6 showed greater percent entrapment efficiency (PEE), adequate particle size and sustained drug release behavior. Formula S6 was integrated into HPMC gel (3%) to prepare nasal gel. Zol SLN nasal gel was subjected to histopathological study to ensure brain targeting. 


Results: It was observed that all prepared Zol SLNs were in the nano-sized range with a polydispersity index of<0.5. In the cholesterol/lecithin combination, higher PEE%, better stability, and less agglomeration inclination were discovered. Results of the release profiles showed that developed Zol-SLNs were able to release Zolmitriptan in a sustained manner. Histopathological study of the brain tissues showed that Zolmitriptan SLN nasal gel can reach brain cells and localized for 24 h although the hydrophobicity of the target drug.


Conclusion: Intranasal administration of Solid lipid nanostructure of Zolmitriptan through the olfactory pathway in which it travels from the nasal cavity to brain tissue achieved drug targeting potential of about 90% compared with conventional Zolmitriptan tablets. The small particle size helped them to squeeze themselves through the small opening in the olfactory neurons to the brain via different endo-cystic pathways of neuronal cells in nasal tissue membranes.

Keywords: Zolmitriptan, Solid lipid nanoparticles (SLNs), Migraine, Histopathological examination, Brain targeting

References

1. Youssef NA, Kassem AA, Farid RM, Ismail FA, EL-Massik MA, Boraie NA. A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: preparation, characterization and in vivo evaluation. Int J Pharm 2018;548:609-24.
2. Wagh M, Bora SM. Development and evaluation of elastic niosomal formulation for migraine treatment using TRNA approach. Int J Pharm Sci Res 2018;9:4591-600.
3. Raza A, Ansari TM, Niazi SB. A novel spectrophotometric method for the determination of zolmitriptan in pharmaceutical formulations. J Chin Chem Soc 2007;54:1413-7.
4. Jain R, Nabar S, Dandekar P, Patravale V. Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharm Res 2010;27:655-64.
5. Shiledar RR, Tagalpallewar AA, Kokare CR. Formulation and in vitro evaluation of xanthan gum-based bilayered mucoadhesive buccal patches of zolmitriptan. Carbohydr Polym 2014;101:1234-42.
6. Bayrak Z, Tas C, Tasdemir U, Erol H, Ozkan CK, Savaser A, et al. Formulation of zolmitriptan sublingual tablets prepared by direct compression with different polymers: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2011;78:499-505.
7. Gupta S, Kesarla R, Chotai N, Misra A, Omri A. Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high-pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. Biomed Res Int 2017. https://doi.org/10.1155/2017/5984014
8. WM Pardridge. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2:3–14.
9. Singh GU, Rawat NI, Singh KI, Sarwal AM, Sinha VR. Investigating the potential of an antidepressant intranasal mucoadhesive microemulsion. Int J Pharm Pharm Sci 2018;10:125-32.
10. Rodriguez A, Tatter SB, Debinski W. Neurosurgical techniques for disruption of the blood-brain barrier for glioblastoma treatment. Pharmaceutics 2015;7:175–87.
11. Begunm MY, Gudipati PR. Formulaton and evalution of dasatinib loaded solid lipid nanoparticles. Int J Pharm Pharm Sci 2018;10:15-20.
12. Jain K, Sood S, Gowthamarajan K. Optimization of artemether-loaded NLC for intranasal delivery using central composite design. Drug Delivery 2015;22:940-54.
13. Vijayan V, Aafreen S, Sakthivel S, Reddy KR. Formulation and characterization of solid lipid nanoparticles loaded Neem oil for topical treatment of acne. J Acute Disease 2013;2:282-6.
14. Garud A, Singh D, Garud N. Solid lipid nanoparticles (SLN): method, characterization and applications. Int Curr Pharm J 2012;1:384-93.
15. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 2009;71:349.
16. Shelke S, Shahi S, Jalalpure S, Dhamecha D. Poloxamer 407-based intranasal thermoreversible gel of zolmitriptan-loaded nanoethosomes: formulation, optimization, evaluation and permeation studies. J Liposome Res 2016;26:313-23.
17. Panda N, Reddy AV, Reddy GS, Panda KC. Formulation design and in vitro evaluation of zolmitriptan immediate-release tablets using primojel and AC-Di-Sol. J Pharm Sci Res 2015;7:545.
18. Garud A, Singh D, Garud N. Design and optimization of solid lipid nanoparticles (SLNs) of zolmitriptan for the management of migraine. Ind J Pharm 2013;24:245-52.
19. Mostafa DA, Hashad AM, Abdelreheem AYM. Formulation and evaluation of novel brain targeting drug loaded in lipid-based nanoparticles through the intranasal route for Alzheimer. Int Res J Pharm 2019;10:21-7.
20. Balguri SP, Adelli GR, Majumdar S. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. Eur J Pharm Biopharm 2016;109:224-35.
21. Khalil RM, Abd-Elbary A, Kassem MA. Formulation and characterization of nystatin-loaded nanostructured lipid carriers for topical delivery against cutaneous candidiasis. BJPR 2013;4:490–512.
22. Fatouh AM, Elshafeey AH, Abdelbary A. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics. Drug Des Dev Ther 2017;11:1815-25.
23. Abd-Elal RM, Shamma RN, Rashed HM, Bendas ER. Trans-nasal zolmitriptan novasomes: in vitro preparation, optimization and in vivo evaluation of brain targeting efficiency. Drug Delivery 2016;23:3374-86.
24. Yassin GE, Amer RI, Fayez AM. Carpamazeine loaded vesicular structures for enhanced brain targeting via intranasal route: optimization, in vitro evaluation, and in vivo study. Int J Appl Pharm 2019;11:264-74.
25. Singh S, Dobhal AK, Jain A, Pandit JK, Chakraborty S. Formulation and evaluation of solid lipid nanoparticles of a water-soluble drug. Zidovudine Chem Pharm Bull 2010;58:650.
26. Kuo YC, Wang CC. Cationic solid lipid nanoparticles with primary and quaternary amines for release of saquinavir and biocompatibility with endothelia. Colloids Surfaces B: Biointerfaces 2013;101:101-5.
27. Abdelbary GA, Amin MM, Zakaria MY. Ocular ketoconazole-loaded proniosomal gels: formulation, ex vivo corneal permeation and in vivo studies. Drug Delivery 2017;24:309-19.
28. K Manjunath, JS Reddy, V Venkateswarlu. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 2005;27:127.
29. Varshosaz J, Ghaffari S, Khoshayand MR, Atyabi F, Azarmi S, Kobarfard F. Development and optimization of solid lipid nanoparticles of amikacin by central composite design. J Liposome Res 2010;20:97-104.
30. Shah R, Eldridge D, Palombo E, Harding I. Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential. J Phys Sci 2014;25:59-75.
31. Ruckmani K, Sivakumar M, Ganeshkumar PA. Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. J Nanosci Nanotech 2006;6:2991-5.
32. Asasutjarit R, Lorenzen SI, Sirivichayakul S, Ruxrungtham K, Ruktanonchai U, Ritthidej GC. Effect of solid lipid nanoparticle formulation compositions on their size, zeta potential and potential for in vitro pHIS-HIV-hugag transfection. Pharm Res 2007;24:1098-107.
33. Jain SK, Chourasia MK, Masuriha R, Soni V, Jain A, Jain NK, et al. Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Delivery 2005;12:207-15.
34. Severino P, Andreani T, Macedo AS, Fangueiro JF, Santana MH, Silva AM, et al. Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Delivery 2012. Doi:10.1155/2012/750891.
35. Vivek K, Reddy H, Murthy RS. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech 2007;8:16-24.
36. Muntimadugu E, Dhommati R, Jain A, Challa VG, Shaheen M, Khan W. Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease. Eur J Pharm Sci 2016;92:224-34.
37. Baig MS, Ahad A, Aslam M, Imam SS, Aqil M, Ali A. Application of box–behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: optimization, in vitro release, ocular tolerance, and antibacterial activity. Int J Biol Macromol 2016;85:258-70.
38. Muller RH, MaEder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77.
39. El-Housiny S, Shams Eldeen MA, El-Attar YA, Salem HA, Attia D, Bendas ER, et al. Fluconazole-loaded solid lipid nanoparticles topical gel for the treatment of pityriasis versicolor: formulation and clinical study. Drug Delivery 2018;25:78-90.
Statistics
120 Views | 33 Downloads
Citatons
How to Cite
MOSTAFA, D. A. E., KHALIFA, M. K. A., & GAD, S. S. (2020). ZOLMITRIPTAN BRAIN TARGETING VIA INTRANASAL ROUTE USING SOLID LIPID NANOPARTICLES FOR MIGRAINE THERAPY: FORMULATION, CHARACTERIZATION, IN-VITRO AND IN-VIVO ASSESSMENT. International Journal of Applied Pharmaceutics, 12(2), 86-93. https://doi.org/10.22159/ijap.2020v12i2.36812
Section
Original Article(s)